CIK 0001830487 · Large accelerated filer
Pharvaris N.V.
Sign in to watch- Ticker
- PHVS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- other
- Phone
- 31 (0)71 203 6410
- Business address
- J.H. OORTWEG 21, 2333 CH LEIDEN, LEIDEN, Netherlands
- Former names
- Pharvaris, B.V.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $20,335,217
- in 16 filings, $4.1M under 10b5-1 plans
Net −$20,335,217. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Schikan Johannes Gerardus Christiaan Petrus −$7.0M Director sold 64% of stake
- Lu Peng −$4.7M President sold 67% of stake
- Bjork Elisabeth −$2.0M Director sold 78% of stake
- Lesage Anne −$1.9M Chief Early Development sold 40% of stake
- Abele Stefan Andreas −$1.8M Chief Technical Ops Officer sold 54% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-30 | Lesage Anne Chief Early Development | Option exercise 10b5-1 | +2,972 | $2.59 | $8K | 61,722 |
| 2026-06-30 | Lesage Anne Chief Early Development | Option exercise 10b5-1 | +24,900 | $8.05 | $200K | 86,622 |
| 2026-06-30 | Lesage Anne Chief Early Development | Sale 10b5-1 | −27,872 | $35.48 | $989K | 58,750 |
| 2026-06-30 | Lesage Anne Chief Early Development | Sale 10b5-1 | −30,703 | $35.49 | $1.1M | 93,969 |
| 2026-06-30 | Lesage Anne Chief Early Development | Option exercise · Stock Option (Right to Buy) 10b5-1 | −24,900 | 45,000 | ||
| 2026-06-30 | Lesage Anne Chief Early Development | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,972 | 0 | ||
| 2026-06-29 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale 10b5-1 | −6,888 | $35.05 | $241K | 345,879 |
| 2026-06-29 | Lesage Anne Chief Early Development | Option exercise 10b5-1 | +1,400 | $2.59 | $4K | 57,850 |
| 2026-06-29 | Lesage Anne Chief Early Development | Option exercise 10b5-1 | +900 | $8.05 | $7K | 58,750 |
| 2026-06-29 | Lesage Anne Chief Early Development | Option exercise 10b5-1 | +4,100 | $2.59 | $11K | 56,450 |
| 2026-06-29 | Lesage Anne Chief Early Development | Option exercise 10b5-1 | +4,200 | $8.05 | $34K | 67,050 |
| 2026-06-29 | Lesage Anne Chief Early Development | Sale 10b5-1 | −2,300 | $35.12 | $81K | 56,450 |
| 2026-06-29 | Lesage Anne Chief Early Development | Sale 10b5-1 | −8,300 | $35.05 | $291K | 58,750 |
| 2026-06-29 | Lesage Anne Chief Early Development | Sale 10b5-1 | −6,997 | $35.05 | $245K | 124,672 |
| 2026-06-29 | Lesage Anne Chief Early Development | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,200 | 69,900 | ||
| 2026-06-29 | Lesage Anne Chief Early Development | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,400 | 7,072 | ||
| 2026-06-29 | Lesage Anne Chief Early Development | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,100 | 2,972 | ||
| 2026-06-29 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale 10b5-1 | −2,400 | $35.10 | $84K | 352,767 |
| 2026-06-26 | Lu Peng Chief Medical Officer | Option exercise 10b5-1 | +14,700 | $2.59 | $38K | 80,331 |
| 2026-06-26 | Lu Peng Chief Medical Officer | Sale 10b5-1 | −14,700 | $34.00 | $500K | 65,631 |
Page 4 of 9 · 170 trades